Abstract: The present invention relates to compounds and their use in treatment of disorders mediated by tachykinin receptors, such as the tachykinin receptor 2.

Abstract: The present invention relates to a novel acylating agent, a method for its preparation, and a method of using it for acylating one or more amino groups of an amino acid, a peptide, or a protein. The novel acylating agent may be a compound which comprises a structural element —HN—(CH2)2-(O—((CH2)2)k-O—(CH2)n-CO—, wherein k is an integer in the range of 1-10, and n is an integer in the range of 1-2, being esterified at its —CO-end to the hydroxy group of 3,5-dichloro-2-hydroxy-benzenesulfonic acid (3,5-DC-2-HBSA). This novel acylating agent has an improved stability. Using this agent the acylation process is improved as regards robustness, as well as improving yield and overall production economy. The novel acylating agent is useful for acylating pharmaceutical peptides and proteins such as GLP-1, insulin, pYY, and amylin. The invention also relates to a number of novel GLP-1 precursor peptides and derivatives in which the two N-terminal amino acids have been deleted.

Abstract: The present invention relates to a novel acylating agent, a method for its preparation, and a method of using it for acylating one or more amino groups of an amino acid, a peptide, or a protein. The novel acylating agent may be a compound which comprises a structural element —HN—(CH2)2-(O—((CH2)2)k-O—(CH2)n-CO—, wherein k is an integer in the range of 1-10, and n is an integer in the range of 1-2, being esterified at its —CO-end to the hydroxy group of 3,5-dichloro-2-hydroxy-benzenesulfonic acid (3,5-DC-2-HBSA). This novel acylating agent has an improved stability. Using this agent the acylation process is improved as regards robustness, as well as improving yield and overall production economy. The novel acylating agent is useful for acylating pharmaceutical peptides and proteins such as GLP-1, insulin, pYY, and amylin. The invention also relates to a number of novel GLP-1 precursor peptides and derivatives in which the two N-terminal amino acids have been deleted.

Abstract: The present invention relates to a subsea installation for treatment of hydrocarbons from a subsea well, having a pipe system comprising a first manifold (2) connected to at least one well (1) and at least two first pipe segments (3) with an inlet connected to the manifold (2) and where the first pipe segments (3) comprise at least two outlets, where the first manifold (2) and the first pipe segments (3) are arranged in a first plane and where one of the outlets from the first pipe segments leads to a second manifold (7). According to the invention a second of the outlets from the first pipe segments (3) leads to at least two second pipe segments (9) arranged in a second plane and where at least one of the outlets forms an inlet to the second pipe segments (9), where the second pipe segments (9) comprise at least one outlet leading to a third manifold (12).

Abstract: The present invention relates to a subsea installation for treatment of hydrocarbons from a subsea well, having a pipe system comprising a first manifold (2) connected to at least one well (1) and at least two first pipe segments (3) with an inlet connected to the manifold (2) and where the first pipe segments (3) comprise at least two outlets, where the first manifold (2) and the first pipe segments (3) are arranged in a first plane and where one of the outlets from the first pipe segments leads to a second manifold (7). According to the invention a second of the outlets from the first pipe segments (3) leads to at least two second pipe segments (9) arranged in a second plane and where at least one of the outlets forms an inlet to the second pipe segments (9), where the second pipe segments (9) comprise at least one outlet leading to a third manifold (12).